The tetrapeptide Epithalon (AEDG) enabled human pulmonary fibroblasts to exceed the Hayflick limit of cell divisions, extending replicative lifespan through telomerase activation — demonstrating anti-aging at the cellular replication level.
Key findingEpithalon peptide treatment enabled human somatic cells to overcome the Hayflick division limit (normally ~50 divisions), extending replicative lifesp
What the researchers found
Epithalon peptide treatment enabled human somatic cells to overcome the Hayflick division limit (normally ~50 divisions), extending replicative lifespan through telomerase activation and telomere maintenance.
Why it matters
Advances understanding of anti-aging, peptide-design, immune-function.
How the study worked
in-vitro study examining anti-aging and peptide-design.
What this study cannot tell us
Study-specific limitations; see abstract.
How to read the evidence
preliminary evidence from in-vitro study.
When this study was published
Published in 2004.
The bigger picture
Contributes to peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation potential to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Peptide promotes overcoming of the division limit in human somatic cell.
Bulletin of experimental biology and medicine, 137(5), 503-6
Citation
Khavinson, V Kh; Bondarev, I E; Butyugov, A A; Smirnova, T D. (2004). Peptide promotes overcoming of the division limit in human somatic cell.. Bulletin of experimental biology and medicine, 137(5), 503-6.